Moreover, the incidence of symptomatic LVSD or asymptomatic decrease in LVEF associated with the study drugs was low in this study, which was much lower than the 3.50% reported in the meta-analysis of pertuzumab for HER2-positive breast cancer [32, 33]. The gene discussed is ERBB2; the disease is breast carcinoma.